Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Comedian Jim Gaffigan, whose new stand-up special, 'The Skinny', premieres on Nov. 22 on Hulu, has lost 50 lbs. with the help ...

Ozempic traps the individual, increasing the weight faster when stopped. A woman from US recounted her bad experience with ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...